Clinical laboratory · 2026
PSPH and CXCL2 Predict Treatment Response in First-Episode Schizophrenia: a Retrospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Jingjing
Аннотация
BACKGROUND: The aim was to evaluate serum levels of Phosphoserine Phosphatase (PSPH) and Chemokine C-X-C Motif Ligand 2 (CXCL2) as biomarkers for predicting antipsychotic treatment response in male first-episode schizophrenia patients.
METHODS: Bioinformatics analysis identified upregulated PSPH and CXCL2 expression in PBMCs of schizophrenia patients. Clinical data from 297 male patients (treated with olanzapine from 2019 to 2024) were retrospectively analyzed. After 4 weeks, patients were categorized into improvement (n = 118) and non-improvement (n = 179) groups. Serum PSPH and CXCL2 levels were measured by ELISA. Predictive value was assessed via ROC and multivariate logistic regression.
RESULTS: The non-improvement group had higher PSPH/CXCL2 levels. Both biomarkers correlated positively with PANSS scores (r = 0.249, 0.335; p < 0.001). Logistic regression confirmed PSPH/CXCL2 levels, pre-treatment PANSS, shorter disease duration, and younger age as independent predictors (p < 0.05). Combined PSPH/CXCL2 showed superior predictive performance (AUC = 0.823, p < 0.05).
CONCLUSIONS: Serum levels of PSPH and CXCL2 can be considered as potential biomarkers for predicting the efficacy of antipsychotic treatment in male patients with first-episode schizophrenia.
METHODS: Bioinformatics analysis identified upregulated PSPH and CXCL2 expression in PBMCs of schizophrenia patients. Clinical data from 297 male patients (treated with olanzapine from 2019 to 2024) were retrospectively analyzed. After 4 weeks, patients were categorized into improvement (n = 118) and non-improvement (n = 179) groups. Serum PSPH and CXCL2 levels were measured by ELISA. Predictive value was assessed via ROC and multivariate logistic regression.
RESULTS: The non-improvement group had higher PSPH/CXCL2 levels. Both biomarkers correlated positively with PANSS scores (r = 0.249, 0.335; p < 0.001). Logistic regression confirmed PSPH/CXCL2 levels, pre-treatment PANSS, shorter disease duration, and younger age as independent predictors (p < 0.05). Combined PSPH/CXCL2 showed superior predictive performance (AUC = 0.823, p < 0.05).
CONCLUSIONS: Serum levels of PSPH and CXCL2 can be considered as potential biomarkers for predicting the efficacy of antipsychotic treatment in male patients with first-episode schizophrenia.